Literature DB >> 36239877

The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease.

Zuzana Špacírová1,2,3, Stephen Kaptoge4, Leticia García-Mochón5,6,7, Miguel Rodríguez Barranco5,6,7, María José Sánchez Pérez5,6,7,8, Nicola P Bondonno9,10, Anne Tjønneland9,11, Elisabete Weiderpass12, Sara Grioni13, Jaime Espín5,6,7, Carlotta Sacerdote14, Catarina Schiborn15,16, Giovanna Masala17, Sandra M Colorado-Yohar5,18,19, Lois Kim4, Karel G M Moons20, Gunnar Engström21, Matthias B Schulze15,16,22, Léa Bresson23, Concepción Moreno-Iribas24, David Epstein25,26.   

Abstract

The objective of this article was to assess the cost-effectiveness of screening strategies for cardiovascular diseases (CVD). A decision analytic model was constructed to estimate the costs and benefits of one-off screening strategies differentiated by screening age, sex and the threshold for initiating statin therapy ("uniform" or "age-adjusted") from the Spanish NHS perspective. The age-adjusted thresholds were configured so that the same number of people at high risk would be treated as under the uniform threshold. Health benefit was measured in quality-adjusted life years (QALY). Transition rates were estimated from the European Prospective Investigation into Cancer and Nutrition (EPIC-CVD), a large multicentre nested case-cohort study with 12 years of follow-up. Unit costs of primary care, hospitalizations and CVD care were taken from the Spanish health system. Univariate and probabilistic sensitivity analyses were employed. The comparator was no systematic screening program. The base case model showed that the most efficient one-off strategy is to screen both men and women at 40 years old using a uniform risk threshold for initiating statin treatment (Incremental Cost-Effectiveness Ratio of €3,274/QALY and €6,085/QALY for men and women, respectively). Re-allocating statin treatment towards younger individuals at high risk for their age and sex would not offset the benefit obtained using those same resources to treat older individuals. Results are sensitive to assumptions about CVD incidence rates. To conclude, one-off screening for CVD using a uniform risk threshold appears cost-effective compared with no systematic screening. These results should be evaluated in clinical studies.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cardiovascular disease; Cost-effectiveness; Framingham risk score; Screening; Spain; Statins

Year:  2022        PMID: 36239877     DOI: 10.1007/s10198-022-01533-y

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  32 in total

1.  Global burden of cardiovascular disease.

Authors:  John E Sanderson; Bongani Mayosi; Salim Yusuf; Srinath Reddy; Shengshou Hu; Zhengming Chen; Adam Timmis
Journal:  Heart       Date:  2007-10       Impact factor: 5.994

2.  Statins for Primary Prevention of Cardiovascular Disease.

Authors:  Henock G Yebyo; Hélène E Aschmann; Milo A Puhan
Journal:  Ann Intern Med       Date:  2019-07-02       Impact factor: 25.391

3.  Trends in age-specific cerebrovascular disease in the European Union.

Authors:  Hui Wang; Wei Sun; Yue Ji; Jing Shi; Qinkao Xuan; Xiuzhi Wang; Junjie Xiao; Xiangqing Kong
Journal:  Int J Clin Exp Med       Date:  2014-11-15

4.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.

Authors:  Frank L J Visseren; François Mach; Yvo M Smulders; David Carballo; Konstantinos C Koskinas; Maria Bäck; Athanase Benetos; Alessandro Biffi; José-Manuel Boavida; Davide Capodanno; Bernard Cosyns; Carolyn Crawford; Constantinos H Davos; Ileana Desormais; Emanuele Di Angelantonio; Oscar H Franco; Sigrun Halvorsen; F D Richard Hobbs; Monika Hollander; Ewa A Jankowska; Matthias Michal; Simona Sacco; Naveed Sattar; Lale Tokgozoglu; Serena Tonstad; Konstantinos P Tsioufis; Ineke van Dis; Isabelle C van Gelder; Christoph Wanner; Bryan Williams
Journal:  Eur Heart J       Date:  2021-09-07       Impact factor: 35.855

5.  Hybrid myocardial perfusion SPECT/CT coronary angiography and invasive coronary angiography in patients with stable angina pectoris lead to similar treatment decisions.

Authors:  Jeroen Schaap; Joris A H de Groot; Koen Nieman; W Bob Meijboom; S Matthijs Boekholdt; Martijn C Post; Jan A S Van der Heyden; Thom L de Kroon; Benno J W M Rensing; Karel G M Moons; J Fred Verzijlbergen
Journal:  Heart       Date:  2012-10-19       Impact factor: 5.994

6.  C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study.

Authors:  Peter W F Wilson; Michael Pencina; Paul Jacques; Jacob Selhub; Ralph D'Agostino; Christopher J O'Donnell
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2008-11-09

7.  European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Authors:  Joep Perk; Guy De Backer; Helmut Gohlke; Ian Graham; Zeljko Reiner; W M Monique Verschuren; Christian Albus; Pascale Benlian; Gudrun Boysen; Renata Cifkova; Christi Deaton; Shah Ebrahim; Miles Fisher; Giuseppe Germano; Richard Hobbs; Arno Hoes; Sehnaz Karadeniz; Alessandro Mezzani; Eva Prescott; Lars Ryden; Martin Scherer; Mikko Syvänne; Wilma J M Scholte Op Reimer; Christiaan Vrints; David Wood; Jose Luis Zamorano; Faiez Zannad
Journal:  Int J Behav Med       Date:  2012-12

8.  Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies.

Authors:  Lisa Pennells; Stephen Kaptoge; Angela Wood; Mike Sweeting; Xiaohui Zhao; Ian White; Stephen Burgess; Peter Willeit; Thomas Bolton; Karel G M Moons; Yvonne T van der Schouw; Randi Selmer; Kay-Tee Khaw; Vilmundur Gudnason; Gerd Assmann; Philippe Amouyel; Veikko Salomaa; Mika Kivimaki; Børge G Nordestgaard; Michael J Blaha; Lewis H Kuller; Hermann Brenner; Richard F Gillum; Christa Meisinger; Ian Ford; Matthew W Knuiman; Annika Rosengren; Debbie A Lawlor; Henry Völzke; Cyrus Cooper; Alejandro Marín Ibañez; Edoardo Casiglia; Jussi Kauhanen; Jackie A Cooper; Beatriz Rodriguez; Johan Sundström; Elizabeth Barrett-Connor; Rachel Dankner; Paul J Nietert; Karina W Davidson; Robert B Wallace; Dan G Blazer; Cecilia Björkelund; Chiara Donfrancesco; Harlan M Krumholz; Aulikki Nissinen; Barry R Davis; Sean Coady; Peter H Whincup; Torben Jørgensen; Pierre Ducimetiere; Maurizio Trevisan; Gunnar Engström; Carlos J Crespo; Tom W Meade; Marjolein Visser; Daan Kromhout; Stefan Kiechl; Makoto Daimon; Jackie F Price; Agustin Gómez de la Cámara; J Wouter Jukema; Benoît Lamarche; Altan Onat; Leon A Simons; Maryam Kavousi; Yoav Ben-Shlomo; John Gallacher; Jacqueline M Dekker; Hisatomi Arima; Nawar Shara; Robert W Tipping; Ronan Roussel; Eric J Brunner; Wolfgang Koenig; Masaru Sakurai; Jelena Pavlovic; Ron T Gansevoort; Dorothea Nagel; Uri Goldbourt; Elizabeth L M Barr; Luigi Palmieri; Inger Njølstad; Shinichi Sato; W M Monique Verschuren; Cherian V Varghese; Ian Graham; Oyere Onuma; Philip Greenland; Mark Woodward; Majid Ezzati; Bruce M Psaty; Naveed Sattar; Rod Jackson; Paul M Ridker; Nancy R Cook; Ralph B D'Agostino; Simon G Thompson; John Danesh; Emanuele Di Angelantonio
Journal:  Eur Heart J       Date:  2019-02-14       Impact factor: 29.983

Review 9.  Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease.

Authors:  Mariana Dyakova; Saran Shantikumar; Jill L Colquitt; Christian M Drew; Morag Sime; Joanna MacIver; Nicola Wright; Aileen Clarke; Karen Rees
Journal:  Cochrane Database Syst Rev       Date:  2016-01-29

10.  A new selection method to increase the health benefits of CVD prevention strategies.

Authors:  Ghizelda R Lagerweij; G Ardine de Wit; Karel Gm Moons; Yvonne T van der Schouw; Wm Monique Verschuren; Jannick An Dorresteijn; Hendrik Koffijberg
Journal:  Eur J Prev Cardiol       Date:  2018-02-07       Impact factor: 7.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.